文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

常染色体显性遗传与散发性早发型阿尔茨海默病的分子神经影像学

Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease.

作者信息

Iaccarino Leonardo, Llibre-Guerra Jorge J, McDade Eric, Edwards Lauren, Gordon Brian, Benzinger Tammie, Hassenstab Jason, Kramer Joel H, Li Yan, Miller Bruce L, Miller Zachary, Morris John C, Mundada Nidhi, Perrin Richard J, Rosen Howard J, Soleimani-Meigooni David, Strom Amelia, Tsoy Elena, Wang Guoqiao, Xiong Chengjie, Allegri Ricardo, Chrem Patricio, Vazquez Silvia, Berman Sarah B, Chhatwal Jasmeer, Masters Colin L, Farlow Martin R, Jucker Mathias, Levin Johannes, Salloway Stephen, Fox Nick C, Day Gregory S, Gorno-Tempini Maria Luisa, Boxer Adam L, La Joie Renaud, Bateman Randall, Rabinovici Gil D

机构信息

Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA 94158, USA.

The Dominantly Inherited Alzheimer Network (DIAN), St Louis, MO 63108, USA.

出版信息

Brain Commun. 2024 May 3;6(3):fcae159. doi: 10.1093/braincomms/fcae159. eCollection 2024.


DOI:10.1093/braincomms/fcae159
PMID:38784820
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11114609/
Abstract

Approximately 5% of Alzheimer's disease patients develop symptoms before age 65 (early-onset Alzheimer's disease), with either sporadic (sporadic early-onset Alzheimer's disease) or dominantly inherited (dominantly inherited Alzheimer's disease) presentations. Both sporadic early-onset Alzheimer's disease and dominantly inherited Alzheimer's disease are characterized by brain amyloid-β accumulation, tau tangles, hypometabolism and neurodegeneration, but differences in topography and magnitude of these pathological changes are not fully elucidated. In this study, we directly compared patterns of amyloid-β plaque deposition and glucose hypometabolism in sporadic early-onset Alzheimer's disease and dominantly inherited Alzheimer's disease individuals. Our analysis included 134 symptomatic sporadic early-onset Alzheimer's disease amyloid-Positron Emission Tomography (PET)-positive cases from the University of California, San Francisco, Alzheimer's Disease Research Center (mean ± SD age 59.7 ± 5.6 years), 89 symptomatic dominantly inherited Alzheimer's disease cases (age 45.8 ± 9.3 years) and 102 cognitively unimpaired non-mutation carriers from the Dominantly Inherited Alzheimer Network study (age 44.9 ± 9.2). Each group underwent clinical and cognitive examinations, C-labelled Pittsburgh Compound B-PET and structural MRI. F-Fluorodeoxyglucose-PET was also available for most participants. Positron Emission Tomography scans from both studies were uniformly processed to obtain a standardized uptake value ratio (PIB cerebellar grey reference and FDG pons reference) images. Statistical analyses included pairwise global and voxelwise group comparisons and group-independent component analyses. Analyses were performed also adjusting for covariates including age, sex, Mini-Mental State Examination, apolipoprotein ε4 status and average composite cortical of standardized uptake value ratio. Compared with dominantly inherited Alzheimer's disease, sporadic early-onset Alzheimer's disease participants were older at age of onset (mean ± SD, 54.8 ± 8.2 versus 41.9 ± 8.2, Cohen's = 1.91), with more years of education (16.4 ± 2.8 versus 13.5 ± 3.2, = 1) and more likely to be apolipoprotein ε4 carriers (54.6% ε4 versus 28.1%, Cramer's = 0.26), but similar Mini-Mental State Examination (20.6 ± 6.1 versus 21.2 ± 7.4, = 0.08). Sporadic early-onset Alzheimer's disease had higher global cortical Pittsburgh Compound B-PET binding (mean ± SD standardized uptake value ratio, 1.92 ± 0.29 versus 1.58 ± 0.44, = 0.96) and greater global cortical F-fluorodeoxyglucose-PET hypometabolism (mean ± SD standardized uptake value ratio, 1.32 ± 0.1 versus 1.39 ± 0.19, = 0.48) compared with dominantly inherited Alzheimer's disease. Fully adjusted comparisons demonstrated relatively higher Pittsburgh Compound B-PET standardized uptake value ratio in the medial occipital, thalami, basal ganglia and medial/dorsal frontal regions in dominantly inherited Alzheimer's disease versus sporadic early-onset Alzheimer's disease. Sporadic early-onset Alzheimer's disease showed relatively greater F-fluorodeoxyglucose-PET hypometabolism in Alzheimer's disease signature temporoparietal regions and caudate nuclei, whereas dominantly inherited Alzheimer's disease showed relatively greater hypometabolism in frontal white matter and pericentral regions. Independent component analyses largely replicated these findings by highlighting common and unique Pittsburgh Compound B-PET and F-fluorodeoxyglucose-PET binding patterns. In summary, our findings suggest both common and distinct patterns of amyloid and glucose hypometabolism in sporadic and dominantly inherited early-onset Alzheimer's disease.

摘要

约5%的阿尔茨海默病患者在65岁之前出现症状(早发性阿尔茨海默病),表现为散发性(散发性早发性阿尔茨海默病)或显性遗传(显性遗传性阿尔茨海默病)。散发性早发性阿尔茨海默病和显性遗传性阿尔茨海默病均以脑淀粉样β蛋白积聚、tau缠结、代谢减退和神经退行性变为特征,但这些病理变化在部位和程度上的差异尚未完全阐明。在本研究中,我们直接比较了散发性早发性阿尔茨海默病和显性遗传性阿尔茨海默病个体中淀粉样β斑块沉积和葡萄糖代谢减退的模式。我们的分析纳入了来自加利福尼亚大学旧金山分校阿尔茨海默病研究中心的134例有症状的散发性早发性阿尔茨海默病淀粉样正电子发射断层扫描(PET)阳性病例(平均±标准差年龄59.7±5.6岁)、89例有症状的显性遗传性阿尔茨海默病病例(年龄45.8±9.3岁)以及来自显性遗传性阿尔茨海默病网络研究的102例认知未受损的非突变携带者(年龄44.9±9.2岁)。每组均接受了临床和认知检查、¹¹C标记的匹兹堡化合物B-PET和结构MRI检查。大多数参与者也进行了¹⁸F-氟脱氧葡萄糖-PET检查。两项研究的正电子发射断层扫描均进行统一处理,以获得标准化摄取值比率(PIB小脑灰质参考和FDG脑桥参考)图像。统计分析包括成对的整体和体素组比较以及组独立成分分析。分析还对包括年龄、性别、简易精神状态检查、载脂蛋白ε4状态和标准化摄取值比率的平均复合皮质等协变量进行了校正。与显性遗传性阿尔茨海默病相比,散发性早发性阿尔茨海默病参与者发病年龄更大(平均±标准差,54.8±8.2岁对41.9±8.2岁,Cohen's d = 1.91),受教育年限更多(16.4±2.8年对13.5±3.2年,t = 1),更可能是载脂蛋白ε4携带者(54.6%为ε4对28.1%,Cramer's V = 0.26),但简易精神状态检查结果相似(20.6±6.1对21.2±7.4,t = 0.08)。散发性早发性阿尔茨海默病的整体皮质匹兹堡化合物B-PET结合更高(平均±标准差标准化摄取值比率,1.92±0.29对1.58±0.44,t = 0.96),且整体皮质¹⁸F-氟脱氧葡萄糖-PET代谢减退更明显(平均±标准差标准化摄取值比率,1.32±0.1对1.39±0.19,t = 0.48),与显性遗传性阿尔茨海默病相比。完全校正后的比较表明,与散发性早发性阿尔茨海默病相比,显性遗传性阿尔茨海默病在内侧枕叶、丘脑、基底神经节和内侧/背侧额叶区域的匹兹堡化合物B-PET标准化摄取值比率相对较高。散发性早发性阿尔茨海默病在阿尔茨海默病特征性颞顶叶区域和尾状核表现出相对更明显的¹⁸F-氟脱氧葡萄糖-PET代谢减退,而显性遗传性阿尔茨海默病在额叶白质和中央周围区域表现出相对更明显的代谢减退。独立成分分析通过突出常见和独特的匹兹堡化合物B-PET和¹⁸F-氟脱氧葡萄糖-PET结合模式,很大程度上重复了这些发现。总之,我们的研究结果表明,散发性和显性遗传性早发性阿尔茨海默病在淀粉样蛋白和葡萄糖代谢减退方面既有共同模式也有不同模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/b12980920cf1/fcae159f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/63058130bd47/fcae159_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/2314b0032d59/fcae159f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/7a5054901ac5/fcae159f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/fbe95e5426c2/fcae159f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/b12980920cf1/fcae159f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/63058130bd47/fcae159_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/2314b0032d59/fcae159f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/7a5054901ac5/fcae159f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/fbe95e5426c2/fcae159f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18cb/11114609/b12980920cf1/fcae159f4.jpg

相似文献

[1]
Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease.

Brain Commun. 2024-5-3

[2]
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.

Lancet Neurol. 2023-1

[3]
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.

Lancet Neurol. 2024-5

[4]
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.

Lancet Neurol. 2025-4

[5]
Longitudinal head-to-head comparison of C-PiB and F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.

Eur J Nucl Med Mol Imaging. 2023-7

[6]
γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).

Lancet Neurol. 2024-9

[7]
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2015-1-28

[8]
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.

Lancet Neurol. 2024-12

[9]
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.

JAMA Neurol. 2022-6-1

[10]
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2017-3-22

引用本文的文献

[1]
Sex and ethnicity in early-onset Alzheimer's disease biomarkers and global function.

Alzheimers Dement (Amst). 2025-8-12

[2]
Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.

Ann Neurol. 2025-8

[3]
Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome.

Ann Neurol. 2025-7

[4]
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer's disease: insights from hybrid PET/MRI and network mapping.

Alzheimers Res Ther. 2025-2-17

本文引用的文献

[1]
Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer's disease.

Brain Commun. 2023-10-18

[2]
Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease.

Alzheimers Dement. 2023-1

[3]
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.

Lancet Neurol. 2022-2

[4]
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous.

Brain. 2022-6-30

[5]
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.

Neurology. 2021-11-2

[6]
The deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid β fibril formation.

Sci Transl Med. 2021-8-11

[7]
Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.

Acta Neuropathol. 2021-10

[8]
Associations between subregional thalamic volume and brain pathology in autosomal dominant Alzheimer's disease.

Brain Commun. 2021-5-10

[9]
Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease.

Brain. 2021-8-17

[10]
Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen.

Alzheimers Dement (Amst). 2021-1-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索